Efficacy of triple combination oral hypoglycaemic therapy using rosiglitazone, metformin and sulphonylurea in lowering HbA1c

Autor: S Garg, J Byrne, SC Wallis, SM Rajbhandari, A Vaidya

Publikováno v: Practical Diabetes International. 20:58-60

Thiazolidinediones are a new class of oral hypoglycaemic agents, which have been reviewed by the National Institute for Clinical Excellence (NICE) and guidelines published. There is ambiguity in the NICE guidelines regarding the use of the triple com

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::74b8e005d13f79e12da9471708abf638
https://doi.org/10.1002/pdi.446

Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort

Autor: Mh, Abdul-Aziz, Lipman J, Akova M, Bassetti M, Jj, Waele, Dimopoulos G, Dulhunty J, Km, Kaukonen, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Sc, Wallis, Ja, Roberts, Dali, Study Group

Publikováno v: Europe PubMed Central

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::4f079959b9842d62cadadc53c688b1cf
http://europepmc.org/abstract/med/26433783

Extended versus bolus infusion of meropenem and piperacillin: A pharmacokinetic analysis

Autor: De Waele J, Mieke Carlier, Hoste E, Depuydt P, Decruyenaere J, Sc, Wallis, Lipman J, Ja, Roberts

Publikováno v: Scopus-Elsevier
Ghent University Academic Bibliography
Europe PubMed Central

Extended infusion of beta-lactam antibiotics has been advocated as a method for optimizing antibiotic exposure in critically ill patients. The objective of this study was to compare the pharmacokinetics/pharmacodynamics of extended infusion versus bo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::2d34bfd6da1bd4f7388056295aaaea07
http://www.scopus.com/inward/record.url?eid=2-s2.0-84920461871&partnerID=MN8TOARS

Safety, tolerability and pharmacokinetics of subcutaneous meropenem as an alternative to intravenous administration.

Autor: Murray F; Department of Infectious Diseases, Fiona Stanley Fremantle Hospitals Group, Murdoch, Western Australia, Australia, 6150., Yoo O; Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia, 6009.; Pharmacy, School of Allied Health, The University of Western Australia, Perth, Western Australia, Australia, 6009.; Institute for Paediatric Perioperative Excellence, The University of Western Australia, Perth, Western Australia, Australia, 6009., Brophy-Williams S; Department of Infectious Diseases, Fiona Stanley Fremantle Hospitals Group, Murdoch, Western Australia, Australia, 6150., Rawlins M; Department of Pharmacy, Fiona Stanley Fremantle Hospitals Group, Murdoch, Western Australia, Australia, 6150., Wallis SC; University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia., Roberts JA; University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia.; Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane, Australia.; Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia.; Division of Anaesthesiology Critical Care Emergency and Pain Medicine, Nîmes University Hospital, University of Montpellier, Nîmes, France., Raby E; Department of Infectious Diseases, Fiona Stanley Fremantle Hospitals Group, Murdoch, Western Australia, Australia, 6150.; Department of Microbiology, PathWest Laboratory Medicine, Fiona Stanley Hospital, Murdoch, Western Australia, Australia, 6150., Salman S; Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia, 6009., Manning L; Department of Infectious Diseases, Fiona Stanley Fremantle Hospitals Group, Murdoch, Western Australia, Australia, 6150.; Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia, 6009.; Medical School, Faculty of Health and Medical Sciences, The University of Western Australia, Harry Perkins Research Institute, Fiona Stanley Hospital, PO Box 404, Bull Creek 6149, Crawley, Western Australia, Australia, 6009.

Publikováno v: The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2025 Jan 03; Vol. 80 (1), pp. 209-215.

Population pharmacokinetics of caspofungin in critically ill patients receiving extracorporeal membrane oxygenation-an ASAP ECMO study.

Autor: Abdul-Aziz MH; University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.; Department of Clinical Pharmacy, Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam, Malaysia., Diehl A; Department of Intensive Care and Hyperbaric Medicine, The Alfred Hospital, Melbourne, Victoria, Australia.; School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia., Liu X; University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia., Cheng V; University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia., Corley A; Critical Care Research Group and Adult Intensive Care Services, The Prince Charles Hospital, Brisbane, Queensland, Australia., Gilder E; Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland, New Zealand., Levkovich B; Experiential Development and Graduate Education and Centre for Medicines Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia., McGuinness S; Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland, New Zealand., Ordonez J; University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia., Parke R; Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland, New Zealand.; School of Nursing, The University of Auckland, Auckland, New Zealand., Pellegrino V; Department of Intensive Care and Hyperbaric Medicine, The Alfred Hospital, Melbourne, Victoria, Australia.; School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia., Wallis SC; University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia., Fraser JF; Critical Care Research Group and Adult Intensive Care Services, The Prince Charles Hospital, Brisbane, Queensland, Australia.; Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.; Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia.; Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Queensland, Australia., Shekar K; Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.; Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia.; Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Queensland, Australia., Roberts JA; University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.; Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane, Queensland, Australia.; Department of Intensive Care Medicine and Pharmacy, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.; Division of Anaesthesiology Critical Care Emergency and Pain Medicine, Nîmes University Hospital, University of Montpellier, Montpellier, France.

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2024 Dec 18, pp. e0143524. Date of Electronic Publication: 2024 Dec 18.